Logo image of ALLR

ALLARITY THERAPEUTICS INC (ALLR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALLR - US0167445008 - Common Stock

1.33 USD
+0.08 (+6.4%)
Last: 11/28/2025, 8:12:25 PM
1.301 USD
-0.03 (-2.18%)
After Hours: 11/28/2025, 8:12:25 PM
Fundamental Rating

2

Taking everything into account, ALLR scores 2 out of 10 in our fundamental rating. ALLR was compared to 533 industry peers in the Biotechnology industry. While ALLR seems to be doing ok healthwise, there are quite some concerns on its profitability. ALLR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALLR had negative earnings in the past year.
ALLR had a negative operating cash flow in the past year.
In the past 5 years ALLR always reported negative net income.
In the past 5 years ALLR always reported negative operating cash flow.
ALLR Yearly Net Income VS EBIT VS OCF VS FCFALLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of ALLR (-116.28%) is worse than 78.61% of its industry peers.
The Return On Equity of ALLR (-202.65%) is worse than 67.35% of its industry peers.
Industry RankSector Rank
ROA -116.28%
ROE -202.65%
ROIC N/A
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALLR Yearly ROA, ROE, ROICALLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

ALLR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLR Yearly Profit, Operating, Gross MarginsALLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALLR has more shares outstanding
Compared to 5 years ago, ALLR has more shares outstanding
The debt/assets ratio for ALLR has been reduced compared to a year ago.
ALLR Yearly Shares OutstandingALLR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M
ALLR Yearly Total Debt VS Total AssetsALLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ALLR has an Altman-Z score of -8.97. This is a bad value and indicates that ALLR is not financially healthy and even has some risk of bankruptcy.
ALLR has a worse Altman-Z score (-8.97) than 70.17% of its industry peers.
There is no outstanding debt for ALLR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.97
ROIC/WACCN/A
WACCN/A
ALLR Yearly LT Debt VS Equity VS FCFALLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 2.31 indicates that ALLR has no problem at all paying its short term obligations.
With a Current ratio value of 2.31, ALLR is not doing good in the industry: 71.29% of the companies in the same industry are doing better.
ALLR has a Quick Ratio of 2.31. This indicates that ALLR is financially healthy and has no problem in meeting its short term obligations.
ALLR has a Quick ratio of 2.31. This is in the lower half of the industry: ALLR underperforms 69.04% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.31
ALLR Yearly Current Assets VS Current LiabilitesALLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

ALLR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.71%, which is quite impressive.
EPS 1Y (TTM)99.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALLR will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.92% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.94%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5Y18.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALLR Yearly Revenue VS EstimatesALLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2M 4M 6M 8M
ALLR Yearly EPS VS EstimatesALLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -500K -1M -1.5M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALLR. In the last year negative earnings were reported.
Also next year ALLR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLR Price Earnings VS Forward Price EarningsALLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLR Per share dataALLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20K -40K -60K -80K -100K

4.3 Compensation for Growth

ALLR's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

ALLR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLARITY THERAPEUTICS INC

NASDAQ:ALLR (11/28/2025, 8:12:25 PM)

After market: 1.301 -0.03 (-2.18%)

1.33

+0.08 (+6.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-31 2026-03-31/amc
Inst Owners1.95%
Inst Owner Change429.6%
Ins OwnersN/A
Ins Owner Change4.45%
Market Cap21.03M
Revenue(TTM)N/A
Net Income(TTM)-24.66M
Analysts82.86
Price Target9.44 (609.77%)
Short Float %2.61%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.78%
PT rev (3m)2.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.59
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)-123690
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS0.84
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -116.28%
ROE -202.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.31
Altman-Z -8.97
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.54%
EPS Next Y99.94%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5Y18.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.21%
OCF growth 3YN/A
OCF growth 5YN/A

ALLARITY THERAPEUTICS INC / ALLR FAQ

Can you provide the ChartMill fundamental rating for ALLARITY THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ALLR.


What is the valuation status for ALLR stock?

ChartMill assigns a valuation rating of 1 / 10 to ALLARITY THERAPEUTICS INC (ALLR). This can be considered as Overvalued.


What is the profitability of ALLR stock?

ALLARITY THERAPEUTICS INC (ALLR) has a profitability rating of 0 / 10.